Any current/future capex/capital investment/strategic investment?

Planned capex for the year is approximately Rs.150 crore. Part of the capex will go towards a new R&D facility. Some capex will be used for de-bottlenecking one or two products with good opportunity. New Multi-Purpose Plant (MPP) at Dahej SEZ started trial production in June; revenue expected from Q2 onwards. Expected capacity utilization of the new MPP is about 60% in the first year, improving in subsequent years. Capex will support seeding new opportunities, scaling new products, and expanding manufacturing capabilities. Focus on longer-term investment decisions evaluated via internal rate o

Any current/future new fundraising through debt or equity?

No specific mention of any new fundraising through debt or equity in the current quarter. The company repaid Rs. 25 crore of working capital loan during the quarter, indicating a focus on reducing debt. Capex for the year is expected to be around Rs. 150 crore, to be funded presumably through internal accruals. Future investments include R&D and manufacturing capacity expansion, but no explicit plans for external fundraising are stated. Management emphasizes sustaining cash flow and EBITDA, with no indication of raising new capital via equity or debt in the near term.

Future growth expectations in sales/revenue/volumes?

Near term growth to be volume-led due to price volatility and sharp price reductions. Domestic consumption expected to improve as the monsoon progresses, potentially driving volume growth. Export markets remain cautious due to inventory overhang and price erosions, especially for products like Acephate. New products and better product mix targeted to improve realizations and drive volume growth. Trial production at new Multi-Purpose Plant (MPP) started; commercial revenue expected from Q2, with around 60% capacity utilization in the first year. Innovation Turnover Index (new products contribut

Future growth expectations in earnings/operating earnings/profits/EPS?

Near-term challenges due to sharp price reductions and global demand reduction caused by channel inventory overhang. Volume-led growth is expected to be the key driver; price-led revenue growth will be challenging. Focus on improving realizations through better product mix and dynamic pricing. Diverse portfolio across domestic/international markets, crop nutrition, and seeds business offers stability. Investments in R&D, product development, and manufacturing to support sustainable growth. Margin improvement dependent on multiple factors, including seasonality and domestic business performance

Rallis IndiaQ1 FY24Fertilizers & Agrochemicals

Rallis India Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹189.54P/E: 16.1Market Cap: ₹3.7K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 4

Near term growth to be volume-led due to price volatility and sharp price reductions.
Domestic consumption expected to improve as the monsoon progresses, potentially driving volume growth.
Export markets remain cautious due to inventory overhang and price erosions, especially for products like Acephate.
New products and better product mix targeted to improve realizations and drive volume growth.
Trial production at new Multi-Purpose Plant (MPP) started; commercial revenue expected from Q2, with around 60% capacity utilization in the first year.
Innovation Turnover Index (new products contribution) aims to increase, supporting sustainable growth.
Overall revenue growth challenged by global demand reduction and pricing pressures but supported by diversified portfolio across domestic/international crop protection, nutrition, and seeds.
Focus on improving collections and managing inventory to support cash flow and EBITDA.
Optimism on volume recovery in international markets like Brazil if upcoming seasons perform well.

Margin guidance

Category 3

Near-term challenges due to sharp price reductions and global demand reduction caused by channel inventory overhang.
Volume-led growth is expected to be the key driver; price-led revenue growth will be challenging.
Focus on improving realizations through better product mix and dynamic pricing.
Diverse portfolio across domestic/international markets, crop nutrition, and seeds business offers stability.
Investments in R&D, product development, and manufacturing to support sustainable growth.
Margin improvement dependent on multiple factors, including seasonality and domestic business performance.
Innovation Turnover Index targeted at ~15% to support new product scaling.
New manufacturing facility (MPP) expected to achieve ~60% utilization in the first year, with improvement next year.
Overall, earnings growth is cautiously optimistic, hinging on volume recovery, product launches, and improved pricing realizations.

See what Rallis India management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

No specific mention of any new fundraising through debt or equity in the current quarter.
The company repaid Rs. 25 crore of working capital loan during the quarter, indicating a focus on reducing debt.
Capex for the year is expected to be around Rs. 150 crore, to be funded presumably through internal accruals.
Future investments include R&D and manufacturing capacity expansion, but no explicit plans for external fundraising are stated.
Management emphasizes sustaining cash flow and EBITDA, with no indication of raising new capital via equity or debt in the near term.

Order book

The transcript does not provide specific details regarding the current or expected order book or pending orders for the company. However, related insights can be summarized as: - Channel inventory in domestic and international markets remains high, affecting near-term sales decisions and volume growth. - Trade is cautious, deciding purchases closer to the consumption period due to inventory overhang and expected price drops. - Q1 is largely a placement season; clearer liquidation and demand trends are expected in Q2. - For export markets, particularly for Acephate in Brazil, inventory and price pressures are significant, but quantitative inventory data is not available. - New product launches and network expansion efforts aim to drive volume growth in upcoming quarters. - Management is optimistic about demand picking up in Q2 with the start of the Kharif season and improved monsoon conditions. No explicit figures or order backlog details were disclosed.

See what Rallis India management said on order book — free account, 30 seconds.

Capex plans

Yes

Planned capex for the year is approximately Rs.150 crore.
Part of the capex will go towards a new R&D facility.
Some capex will be used for de-bottlenecking one or two products with good opportunity.
New Multi-Purpose Plant (MPP) at Dahej SEZ started trial production in June; revenue expected from Q2 onwards.
Expected capacity utilization of the new MPP is about 60% in the first year, improving in subsequent years.
Capex will support seeding new opportunities, scaling new products, and expanding manufacturing capabilities.
Focus on longer-term investment decisions evaluated via internal rate of return.
Efforts ongoing to reduce dependency on China for raw materials through capex and portfolio diversification.

Track Rallis India — get its next earnings analysis in your feed

How does Rallis India rank vs peers in Fertilizers & Agrochemicals?

Pro feature

ThisRallis India

Rev 4Mar 3

See where Rallis India sits in Fertilizers & AgrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Rallis India rank in Fertilizers & Agrochemicals?

Compare Rallis India against every Fertilizers & Agrochemicals company (Q1 FY24) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

What Rallis India's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Dhanuka Agritech Ltd (Q2 FY27)
657.51 Crores . Key investor presentation takeaways from Dhanuka Agritech Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
Sharda Cropchem Ltd (Q2 FY27)
1,051.7 Cr, up 13% YoY (Q2 FY26: Rs. Key investor presentation takeaways from Sharda Cropchem Ltd's Q2 FY27 investor presentation — and how it ranks against sec
Paradeep Phosphates Ltd (Q2 FY27)
Revenue from operations for the quarter ended 30 September 2026: Rs 7,164.06 crores . Key results statement takeaways from Paradeep Phosphates Ltd's Q2 FY27 ear
Astec Lifescienc (Q2 FY27)
2.3% YoY decline. Key results statement takeaways from Astec Lifescienc's Q2 FY27 results statement — and how it ranks against sector peers.

Compare:vs Coromandel Inter vs UPL Ltd vs F A C T

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →